[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575790":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":40,"collaborators":7,"id":44,"slug":7,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","PD-1 \u002F PD-L1 monoclonal antibody","Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study.",[14],"Radiotherapy.",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Fei Ma","CONTACT","010-87788120","drmafei@126.com",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Cancer Hospital, Chinese Academy of Medical Sciences","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":31,"coordinates":32},"Point",[33,34],116.39723,39.9075,{"lat":34,"lon":33},[37],{"name":38,"role":18,"phone":39,"phoneExt":7,"email":20},"Fei Ma M.D","01087788060",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Ma Fei，MD","Deputy Director of the Department of Medical Oncology","100575790",false,"NCT06776861","A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer","Inclusion Criteria:\n\nSubjects are eligible for inclusion in the study only if all the following criteria apply:\n\n1. Men or women who are 18 years of age or older on the day of signing the informed consent;\n2. Patients with advanced breast cancer that is inoperable or has metastasized, confirmed by histology or cytology;\n3. Patients who, after MDT discussion at the metastatic breast cancer stage, are considered suitable for radiotherapy and have completed radiotherapy;\n4. Patients who have previously received and continue to use immunotherapy, or are planned to receive immunotherapy, and are scheduled to receive a systemic treatment regimen including immunotherapy as chosen by the physician within 3 weeks after completing radiotherapy;\n5. Patients with a traceable medical history during treatment;\n6. Subjects who are able to sign an informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Subjects with brain metastases or leptomeningeal metastases; if there are any suspected symptoms or signs of CNS involvement, they should be excluded by a cranial MRI scan;\n2. Have not signed the informed consent form;\n3. Pregnant or lactating women;\n4. Other conditions deemed unsuitable for inclusion in the study by the investigator.","ALL","18 Years",{"count":52,"type":53},150,"ESTIMATED","2 Years","OBSERVATIONAL","A prospective, multicenter, observational cohort study assessing the efficacy and safety of radiotherapy-sensitized immunotherapy in advanced breast cancer.",[58],"Advanced Breast Cancer","2026-06-06",{"date":61,"type":62},"2026-06-09","ACTUAL",{"date":64,"type":62},"2024-09-24",{"date":66,"type":53},"2028-09-10",{"name":5,"class":6},1]